South African Serotype 1 Foot-and-Mouth Disease Disrupts Livestock Industry ChainWallstreetcn·Apr 14 at 05:38 PM600201+7.85%600195+1.24%
Huachuang Securities: In the first three quarters, most vaccine varieties saw year-on-year growth in batch approvals, and pet vaccines continued to maintain a high growth rateZhitong·Oct 28, 2025 at 01:15 AM603392-0.13%600201+7.85%
JINYU released its performance for the first three quarters, with a net profit attributable to the parent company of 161 million yuan, a decrease of 4.85%Zhitong·Oct 27, 2025 at 03:03 AM600201+7.85%
JINYU: Plans to repurchase and cancel 120,000 shares of stockZhitong·Oct 27, 2025 at 02:44 AM600201+7.85%
JINYU: The gene-engineered subunit vaccine for bovine gas gangrene (Type A) has obtained a new veterinary drug registration certificateZhitong·Oct 16, 2025 at 03:13 AM600201+7.85%
Huachuang Securities: In August, the growth of vaccines for diarrhea, brucellosis, and feline trivalent was strong, and the raw materials for veterinary drugs are entering a peak season with price increasesZhitong·Sep 30, 2025 at 03:03 AM300119+1.73%600201+7.85%
JINYU released its performance for the first half of the year, with a net profit attributable to the parent company of 60.424 million yuan, a year-on-year decrease of 50.84%Zhitong·Aug 19, 2025 at 03:41 AM600201+7.85%
JINYU's subsidiary has obtained a new veterinary drug registration certificateZhitong·Aug 14, 2025 at 02:39 AM600201+7.85%
Guohai Securities: The "Matthew Effect" in the animal protection industry intensifies, and pet pharmaceuticals and overseas expansion are expected to open up medium to long-term growth spaceZhitong·Aug 14, 2025 at 01:38 AM300119+1.73%688098+4.47%
JINYU and others established a supply chain company in ZhejiangZhitong·Aug 1, 2025 at 12:27 AM600201+7.85%
JINYU's subsidiary has obtained the clinical trial approval for veterinary biological productsZhitong·Jul 25, 2025 at 03:34 AM600201+7.85%
JINYU and related personnel received a warning letter from the Inner Mongolia Securities Regulatory BureauZhitong·Jul 24, 2025 at 02:44 AM600201+7.85%
JINYU's subsidiary has obtained the clinical trial approval for the African swine fever subunit vaccineZhitong·Jul 17, 2025 at 03:41 AM600201+7.85%
The animal vaccine sector continues to rise, with JINYU hitting the daily limitZhitong·Jul 16, 2025 at 12:37 AM300119+1.73%688136+3.63%
JINYU: It is expected that the net profit in the first half of 2025 will decrease by 43.05% to 53.63% year-on-yearZhitong·Jul 14, 2025 at 03:34 AM600201+7.85%
